SBTX — Skinbiotherapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- £52.43m
- £48.64m
- £4.64m
Annual cashflow statement for Skinbiotherapeutics, fiscal year end - June 30th, GBP millions except per share, conversion factor applied.
R2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Interim Report | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -1.5 | -2.99 | -3.01 | -2.95 | -0.715 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 0.061 | 0.053 | 0.001 | 0.037 | -0.407 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.123 | 0.227 | 0.309 | 0.01 | -0.54 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -1.56 | -2.67 | -2.65 | -2.73 | -1.24 |
| Capital Expenditures | -0.112 | -0.097 | -0.165 | -0.198 | -0.159 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | — | — | -2.1 | -1.46 |
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.112 | -0.097 | -0.165 | -2.3 | -1.62 |
| Financing Cash Flow Items | — | — | — | -0.037 | -0.063 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 4.12 | -0.035 | 2.32 | 4.51 | 6.83 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 2.45 | -2.8 | -0.493 | -0.511 | 3.98 |